Viewpoint Molecular Targeting is presenting at #BiotechShowcase! Join us in San Francisco this January 9th at 10:00 am PST to attend our presentation about our pipeline featuring our leading lead-212-based alpha-particle radiotherapies. Register: lnkd.in/gJD8Vydc

Have you seen our new MOA video? If not, be sure to check it out here: vimeo.com/654514833/fa84fc5e… #Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

Viewpoint Molecular Targeting® to Present at the B. Riley Radiation Oncology Investor Day. bit.ly/3sbDYik @BRileyFinancial #Theragnostics #Radiopharmaceuticals #Radiotherapy

Viewpoint Molecular Targeting® Appoints Thijs Spoor as Chief Executive Officer. bit.ly/33F25fB #Theragnostics #Radiopharmaceuticals #Radiotherapy

Sign up for email alerts to stay up to date with our latest communications and happenings! bit.ly/3hTazEo #Radiopharmaceuticals #Theranostics

4 in 10 #cancer diagnoses in the U.S. are associated with preventable risk factors. In recognition of #NationalCancerPreventionMonth, we encourage you to learn more at bit.ly/3r3yvcI. @AACRFoundation

Today is #WorldCancerDay. This year’s focus is on understanding and recognizing the inequities in cancer care around the globe. Learn more and how you can help to #CloseTheCareGap here: bit.ly/2E0iGLK #Radiopharmaceuticals #Theranostics

Dr. Michael K. Schultz, Co-Founder and Chief Science Officer of Viewpoint, provides insight behind the power of theranostics to cancer therapy. @InvestorVirtual #VirtualInvestor #Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

We are presenting today at 11:00 AM ET at the JTC #VirtualInvestor 2022 Top Picks Conference. Access our webcast at bit.ly/3F6gNJf @InvestorVirtual

#DontMissIt! We are presenting at the upcoming JTC #VirtualInvestor 2022 Top Picks Conference on Tuesday, January 25th at 11:00 AM ET. Pre-submit your questions here: bit.ly/3pTkXjP @InvestorVirtual

Viewpoint Molecular Targeting® to Present at the Virtual Investor 2022 Top Picks Conference. bit.ly/3rEpq9r @InvestorVirtual #VirtualInvestor

Our Co-Founder and CSO, Dr. Michael K. Schultz, has confidence in the Company’s approach to developing alpha-particle #radiopharmaceuticals. #Theranostics #MetastaticMelanoma #NeuroendocrineTumors @InvestorVirtual #VirtualInvestor

Have you seen our new MOA video? If not, be sure to check it out here: vimeo.com/654514833/fa84fc5e… #Theranostics #Radiopharmaceuticals #MetastaticMelanoma #NeuroendocrineTumors

Our Co-Founder and CEO, Dr. Frances L. Johnson, highlights our unique approach to developing #radiopharmaceuticals. #Theranostics #MetastaticMelanoma #NeuroendocrineTumors @InvestorVirtual #VirtualInvestor

#DontMissIt: Our presentation at the H.C. Wainwright BioConnect Conference is now available! Access the webcast here: bit.ly/3JGjNzq @HCWCO #HCWCO

#MarkYourCalendars: We are participating in the upcoming H.C. Wainwright BioConnect Conference. Access the event here: bit.ly/3JGjNzq @HCWCO #HCWCO

Viewpoint Molecular Targeting® to Present at the H.C. Wainwright BioConnect Conference. bit.ly/3G35XVJ @HCWCO #HCWCO #Radiopharmaceuticals #Theranostics #MetastaticMelanoma #NeuroendocrineTumors

Wishing you a prosperous New Year!